» Articles » PMID: 7580112

Vascular Morphology and Angiogenesis in Glial Tumors

Overview
Specialties Pathology
Toxicology
Date 1995 May 1
PMID 7580112
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Intracranial tumor classification is paralleled by a grading system that empirically compares tumor entities with "progression stages" of supratentorial gliomas of the adult. This grading system is an integral part of the WHO classification. Glioma progression has originally been defined by descriptive morphology. In this respect, morphological key features of high-grade gliomas (WHO grades III and IV) are microvascular proliferation and the formation of tumor necroses. Glioma progression is now more accurately defined on the molecular genetic level by a stepwise accumulation of oncogene activation and/or tumor suppressor gene inactivation. Angiogenesis occurs during development and progression of glial tumors. Pathological vessels are a hallmark of malignant glioma and it has therefore been suggested that malignant glioma cells are able to induce neovascularization. Despite the exuberant neovascularisation, however, vascular supply may not be sufficient for tumor areas with high cell proliferation, and necroses may develop. Malignant transformation of blood vessel itself is a rare event but may be the underlying mechanism of gliosarcoma development. The recently purified vascular endothelial growth factor (VEGF) is at present the only mitogen known to selectively act on endothelial cells. Growing evidence suggests that VEGF is the key regulator of developmental and pathological angiogenesis. In vivo, VEGF mRNA is upregulated in a subpopulation of malignant glioma cells adjacent to necroses. Since VEGF is hypoxia-inducible, hypoxia may be an important regulator of VEGF mRNA expression and tumor angiogenesis in vivo. Two tyrosine kinase receptors for VEGF are expressed in vessels which invade the tumor, suggesting that tumor angiogenesis is regulated by a paracrine mechanism.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Sarcomatous transformation of IDH-mutant astrocytoma matching to methylation class oligosarcoma following embolization, a case report.

Landvater R, Tripathy A, Nieblas-Bedolla E, Shao L, Conway K, Al-Holou W Acta Neuropathol Commun. 2024; 12(1):196.

PMID: 39707480 PMC: 11662476. DOI: 10.1186/s40478-024-01908-7.


Microvasculature Features Derived from Hybrid EPI MRI in Non-Enhancing Adult-Type Diffuse Glioma Subtypes.

Arzanforoosh F, Van der Voort S, Incekara F, Vincent A, van den Bent M, Kros J Cancers (Basel). 2023; 15(7).

PMID: 37046796 PMC: 10093697. DOI: 10.3390/cancers15072135.


Isolinderalactone inhibits glioblastoma cell supernatant-induced angiogenesis.

Lee S, Park J, Cho K, Kim H, Shin H Oncol Lett. 2022; 24(4):328.

PMID: 36039052 PMC: 9404699. DOI: 10.3892/ol.2022.13448.


Role of intra-tumoral vasculature imaging features on susceptibility weighted imaging in differentiating primary central nervous system lymphoma from glioblastoma: a multiparametric comparison with pathological validation.

Bhattacharjee R, Gupta M, Singh T, Sharma S, Khanna G, Parvaze S Neuroradiology. 2022; 64(9):1801-1818.

PMID: 35435463 DOI: 10.1007/s00234-022-02946-5.


Vascular Co-Option and Other Alternative Modalities of Growth of Tumor Vasculature in Glioblastoma.

Ribatti D, Pezzella F Front Oncol. 2022; 12:874554.

PMID: 35433447 PMC: 9005970. DOI: 10.3389/fonc.2022.874554.